Summary
“QMSR isn’t about regulatory obligation; it’s about managing business risk, protecting customers, and preserving market share.”
In this episode of the Let's Talk Risk Podcast, host Naveen Agarwal is joined by Steve Silverman to explore a question that’s often left unspoken: Is the FDA ready for QMSR?
Drawing on his experience as a former FDA leader and industry policy expert, Steve acknowledges that the current environment inside the agency is marked by workforce reductions, loss of institutional knowledge, and political disruption. But he also emphasizes that QMSR activation on February 2, 2026, is still very much on track. He cautions companies against “waiting it out” and explains why hoping for delays or informal grace periods is a risky strategy.
The conversation dives into practical implications for manufacturers, including how FDA is preparing its inspectors, what the absence of updated QSIT guidance really means, why MDSAP certification is helpful but not sufficient, and how FDA is signaling stronger expectations around risk-based quality systems, especially in premarket reviews. The episode closes with clear advice for QA/RA leaders on how to frame QMSR readiness as a business risk and strategic opportunity, not just a regulatory exercise.
Chapters
00:00 Why FDA readiness for QMSR matters as much as industry readiness
02:00 Inside FDA: disruption, workforce loss, and institutional impact
04:12 Will QMSR really go live in February 2026?
06:14 Lessons from MDSAP and parallels to QMSR rollout
10:40 How FDA prepares inspectors for a new regulatory framework
15:14 Why MDSAP certification is not a free pass under QMSR
19:14 What FDA inspections may look like in early 2026
27:58 How QA/RA leaders should explain QMSR to the C-suite
Suggested links:
* LTR: Communicating Effectively with Senior Executives.
* LTR: 90-Day QMSR Readiness Action Pan for Leaders.
* Steve’s Substack: What the FDA?.
Key Takeaways
* QMSR will activate on February 2, 2026, companies should not expect delays or extensions.
* FDA has experienced significant disruption, including workforce reductions and loss of expertise, but core regulatory work continues.
* Waiting to see how FDA “handles” QMSR is a high-risk strategy for manufacturers.
* FDA inspectors are being trained internally to transition from QSR to QMSR, even without updated QSIT guidance.
* MDSAP certification can ease the transition but does not replace FDA inspections or guarantee QMSR compliance.
* FDA will continue enforcing recall and adverse event reporting requirements alongside QMSR.
* Firms that demonstrate good-faith progress and a clear quality plan are likely to encounter a more collaborative FDA posture.
* QMSR explicitly elevates risk as a lifecycle concept, spanning premarket, post-market, and business decision-making.
* Leaders should assess their real exposure using post-market data and not assume compliance equals safety.
* QA/RA leaders must translate QMSR work into business risk, market impact, and strategic value for executives.
Keywords
QMSR, FDA readiness, ISO 13485, MDSAP, FDA inspections, quality system regulation, risk-based quality, CAPA, post-market surveillance, QA/RA leadership
About Steve Silverman
Steve Silverman, is the President of The Silverman Group. Steve spent more than a decade at FDA in leadership positions across the Agency. He adds private-sector expertise from consulting and representing industry members. Steve develops strategies that satisfy regulators and promote business needs. He holds a Bachelor’s degree in English Literature, and a JD in Law.
Disclaimer
Information and insights presented in this podcast are for educational purposes only. Views expressed by all speakers are their own and do not reflect those of their respective organizations.
Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards.
Let's Talk Risk! is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
